Clinical Evaluation of Brahmi in Cognitive Decline
Authors/Creators
Description
Brahmi (Bacopa monnieri) is the cornerstone Medhya Rasayana herb in the classical Ayurvedic cognitive repertoire,
used for centuries for memory support, attention enhancement, and broadly the clinical territory modern medicine labels
cognitive decline. Modern clinical evaluation of Brahmi has matured substantially over the past two decades, with
standardised extracts, controlled trials across multiple cognitive populations, and a growing systematic review literature.
Brahmi now sits alongside Ginkgo biloba as one of the most extensively clinically characterised botanical cognitive
interventions, and it increasingly deserves to be taken seriously in European integrative neurology and
integrative-memory clinics. This review covers 54 primary clinical studies published between 2005 and 2021 evaluating
Brahmi in cognitive-relevant indications, grouped under five clinical evaluation frames: B1 (healthy adults and cognitive
enhancement), B2 (mild cognitive impairment), B3 (age-related cognitive decline without formal MCI diagnosis), B4
(neurodegenerative disease including Alzheimer's-type dementia and Parkinson's disease cognitive impairment), and B5
(integrated multi-herb Medhya Rasayana protocols). Each frame is scored with the Brahmi Cognitive Performance Index
(BCPI). Mild cognitive impairment (B2) produced the strongest clinical signal at BCPI 0.844, followed by age-related
cognitive decline (B3) at 0.828 and healthy-adult cognitive enhancement (B1) at 0.806. Neurodegenerative disease (B4)
scored lowest at 0.652, with the evidence supporting adjunctive rather than primary therapeutic use in this population
Files
906_Clinical_Evaluation_Brahmi_Cognitive_Vol2023_Issue1_pp1-9_Journal_Clinical_Ayurveda_Translational.pdf
Additional details
Identifiers
- ISSN
- 3117-8138
Related works
- Is documented by
- Journal article: 3117-8138 (ISSN)
Dates
- Accepted
-
2023-02-04
Software
- Repository URL
- https://stanfordgroup.org/index.php/JCATM/issue/archive
References
- Aguiar, S. and Borowski, T. (2013). Neuropharmacological review of the nootropic herb Bacopa monnieri. Rejuvenation Research, 16(4), 313-326. Benson, S. et al. (2014). An acute, double-blind, placebo-controlled cross-over study of 320 mg and 640 mg doses of Bacopa monnieri. Phytotherapy Research, 28(4), 551-559. Calabrese, C. et al. (2008). Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly. Journal of Alternative and Complementary Medicine, 14(6), 707-713. Dwivedi, S. et al. (2017). Bacopa monnieri as adjunctive therapy in mild Alzheimer's disease. International Journal of Ayurveda Research, 8(3), 178-185